At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 105 enrolled
Drug / intervention
T2762 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III: Comparison of the Efficacy and Safety of T2762 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
In Brief
A Phase 3 clinical trial evaluating T2762 and Vismed® for Dry Eye Syndrome. Completed, enrolled 105 participants across 1 site.
Detailed Summary
Comparison of the efficacy and safety of T2762 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndrome
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedDec 2013
Primary CompletionDec 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedDec 30, 2013
Enrollment StartDec 1, 2013
Primary CompletionDec 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 12.5 years ago
Interventions
T2762device
1 drop in each eye 3 to 6 times daily during 84 days
Vismed®device
1 drop in each eye 3 to 6 times daily during 84 days